相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Erica C. Nakajima et al.
CLINICAL CANCER RESEARCH (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
Coren A. Milbury et al.
PLOS ONE (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
Mohamed E. Salem et al.
JCO PRECISION ONCOLOGY (2022)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Hanna Tukachinsky et al.
CLINICAL CANCER RESEARCH (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States
Qianyi Zhang et al.
HEALTH SERVICES RESEARCH (2021)
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
Gabriela Palma et al.
NPJ PRECISION ONCOLOGY (2021)
KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
J. Weiss et al.
ANNALS OF ONCOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response
Meagan Montesion et al.
CANCER DISCOVERY (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Dongsung Kim et al.
CELL (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A compendium of mutational cancer driver genes
Francisco Martinez-Jimenez et al.
NATURE REVIEWS CANCER (2020)
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database
Gaurav Singal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples
Sally E. Trabucco et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy
Thomas McFall et al.
SCIENCE SIGNALING (2019)
Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D
Christian W. Johnson et al.
CELL REPORTS (2019)
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy
Gerald Li et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Analysis of protein-coding genetic variation in 60,706 humans
Monkol Lek et al.
NATURE (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A global reference for human genetic variation
David M. Altshuler et al.
NATURE (2015)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)